Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Jan M Leerink, Elizabeth A M Feijen, Perry D Moerland, Esmee C de Baat, Remy Merkx, Helena J H van der Pal, Wim J E Tissing, Marloes Louwerens, Marry M van den Heuvel-Eibrink, A Birgitta Versluys, Folkert W Asselbergs, Arjan Sammani, Arco J Teske, Elvira C van Dalen, Margriet van der Heiden-van der Loo, Eline van Dulmen-den Broeder, Andrica C H de Vries, Livia Kapusta, Jacqueline Loonen, Yigal M PintoLeontien C M Kremer, Annelies M C Mavinkurve-Groothuis, Wouter E M Kok

Research output: Contribution to journalArticlepeer-review

Abstract

Background Plasma biomarkers may aid in the detection of anthracycline-related cardiomyopathy (ACMP). However, the currently available biomarkers have limited diagnostic value in long-term childhood cancer survivors. This study sought to identify diagnostic plasma biomarkers for ACMP in childhood cancer survivors. Methods and Results We measured 275 plasma proteins in 28 ACMP cases with left ventricular ejection fraction <45%, 29 anthracycline-treated controls with left ventricular ejection fraction ≥53% matched on sex, time after cancer, and anthracycline dose, and 29 patients with genetically determined dilated cardiomyopathy with left ventricular ejection fraction <45%. Multivariable linear regression was used to identify differentially expressed proteins. Elastic net model, including clinical characteristics, was used to assess discrimination of proteins diagnostic for ACMP. NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the inflammatory markers CCL19 (C-C motif chemokine ligands 19) and CCL20, PSPD (pulmonary surfactant protein-D), and PTN (pleiotrophin) were significantly upregulated in ACMP compared with controls. An elastic net model selected 45 proteins, including NT-proBNP, CCL19, CCL20 and PSPD, but not PTN, that discriminated ACMP cases from controls with an area under the receiver operating characteristic curve (AUC) of 0.78. This model was not superior to a model including NT-proBNP and clinical characteristics (AUC=0.75; P=0.766). However, when excluding 8 ACMP cases with heart failure, the full model was superior to that including only NT-proBNP and clinical characteristics (AUC=0.75 versus AUC=0.50; P=0.022). The same 45 proteins also showed good discrimination between dilated cardiomyopathy and controls (AUC=0.89), underscoring their association with cardiomyopathy. Conclusions We identified 3 specific inflammatory proteins as candidate plasma biomarkers for ACMP in long-term childhood cancer survivors and demonstrated protein overlap with dilated cardiomyopathy.

Original languageEnglish
Pages (from-to)e025935
JournalJournal of the American Heart Association
Volume11
Issue number14
DOIs
Publication statusPublished - 19 Jul 2022

Keywords

  • Anthracyclines/adverse effects
  • Antibiotics, Antineoplastic/adverse effects
  • Biomarkers
  • Cancer Survivors
  • Cardiomyopathies/chemically induced
  • Cardiomyopathy, Dilated
  • Case-Control Studies
  • Child
  • Humans
  • Natriuretic Peptide, Brain
  • Neoplasms/chemically induced
  • Peptide Fragments
  • Stroke Volume
  • Ventricular Function, Left

Fingerprint

Dive into the research topics of 'Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study'. Together they form a unique fingerprint.

Cite this